Literature DB >> 18085522

ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas.

L Venturini1, R Erdas, A Costa, A Gronchi, S Pilotti, N Zaffaroni, Mg Daidone.   

Abstract

Most cancers maintain telomeres by activating telomerase, but a significant minority, mainly of mesenchymal origin, utilize an alternative lengthening of telomeres (ALT) mechanism. We previously showed the presence of ALT, as detected by ALT-associated promyelocytic leukaemia bodies (APBs) by combined promyelocytic leukaemia immunofluorescence and telomere fluorescence-in situ hybridization, in approximately 25% of frozen specimens obtained from adult patient liposarcomas and proved that ALT negatively affects patient prognosis. In the present study, we assessed the reproducibility of APB detection on frozen versus formalin-fixed, paraffin-embedded specimens from the same liposarcoma specimens and investigated the eventual stability of ALT in 103 different lesions from 40 adult patients followed during their disease. Irrespective of liposarcoma subtype, we (1) confirmed the presence of ALT in 21.4% of tumours; (2) demonstrated the reliability of ALT-associated promyelocytic leukaemia body detection in formalin-fixed, paraffin-embedded sections (with qualitative concordance between matched frozen and formalin-fixed, paraffin-embedded samples in 29/30 specimens, and high quantitative agreement, as indicated by a Spearman correlation coefficient of 0.85); and (3) suggested the stability of ALT status during disease evolution, since the ALT mechanism was never acquired in the 29 patients with initially ALT-negative lesions and lost over time in only two of 11 patients with initially ALT-positive liposarcomas. In conclusion, these results confirm the possibility of investigating the ALT mechanism in archival specimens to obtain biologically relevant information on liposarcoma progression, even when the primary lesion is not available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18085522     DOI: 10.1002/path.2288

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

Review 1.  Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends.

Authors:  Song My Hoang; Roderick J O'Sullivan
Journal:  Trends Cancer       Date:  2020-01-23

2.  Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.

Authors:  Jen-Chieh Lee; Yung-Ming Jeng; Jau-Yu Liau; Jia-Huei Tsai; Hung-Han Hsu; Ching-Yao Yang
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

3.  Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis.

Authors:  Lorenza Venturini; Rosita Motta; Alessandro Gronchi; MariaGrazia Daidone; Nadia Zaffaroni
Journal:  BMC Cancer       Date:  2010-06-03       Impact factor: 4.430

4.  Telomerase-independent paths to immortality in predictable cancer subtypes.

Authors:  Stephen T Durant
Journal:  J Cancer       Date:  2012-01-31       Impact factor: 4.207

5.  Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences.

Authors:  Yue Yu; Shashank P Katiyar; Durai Sundar; Zeenia Kaul; Eijiro Miyako; Zhenya Zhang; Sunil C Kaul; Roger R Reddel; Renu Wadhwa
Journal:  Cell Death Dis       Date:  2017-04-20       Impact factor: 8.469

6.  Telomeric Recombination Induced by DNA Damage Results in Telomere Extension and Length Heterogeneity.

Authors:  Haiying Liu; Yujie Xie; Zepeng Zhang; Pingsu Mao; Jingfan Liu; Wenbin Ma; Yong Zhao
Journal:  Neoplasia       Date:  2018-08-14       Impact factor: 5.715

Review 7.  Telomere maintenance mechanisms in cancer: clinical implications.

Authors:  Roger R Reddel
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  Massively parallel single-molecule telomere length measurement with digital real-time PCR.

Authors:  Yongqiang Luo; Ramya Viswanathan; Manoor Prakash Hande; Amos Hong Pheng Loh; Lih Feng Cheow
Journal:  Sci Adv       Date:  2020-08-21       Impact factor: 14.136

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.